Human Genome Sciences 8-K 2012
Documents found in this filing:
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 9, 2012
HUMAN GENOME SCIENCES, INC.
(Exact name of registrant as specified in its charter)
Registrants telephone number, including area code: (301) 309-8504
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Item 2.02. Results of Operations and Financial Condition.
On January 9, 2012, the Company issued the press release attached as Exhibit 99.1 to this Form 8-K, which includes BENLYSTA® sales figures for 2011, guidance regarding cash and investments at year-end 2011 and SG&A and R&D expense for both 2011 and 2012, a business update, and the Companys priority goals for 2012. In addition, certain information relating to weekly gross sales of BENLYSTA and financial guidance are included in Exhibit 99.2, which is incorporated by reference into this Item 2.02.
Item 7.01. Regulation FD Disclosure.
During the week of January 9, 2012, representatives of Human Genome Sciences, Inc. will be attending meetings with investors, analysts and others at the JP Morgan Healthcare Conference in San Francisco, California, and will be presenting at the conference on Monday, January 9, 2012, at 4:30 p.m. Pacific time (7:30 p.m. Eastern time). During these meetings and the presentation and from time to time, the Company will present the slides attached as Exhibit 99.2 to this Form 8-K.
Item 9.01. Financial Statements and Exhibits.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: January 9, 2012
INDEX TO EXHIBITS